General Investor Information EBR Systems, page-272

This is not directly related to EBR, but it serves to demonstrate the appetite and potential for device manufacturers such as Boston Scientific, Medtronics, Abbott, with considerable balance sheets acquiring much smaller entities, in this case Silk Road Medical but could quite easily be EBR:

"Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc."

"Acquisition adds innovative technology for stroke prevention to vascular portfolio

"MARLBOROUGH, Mass., June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is $27.50 per share, reflecting an enterprise value of approximately $1.16 billion.
...
"The TCAR platform developed by Silk Road Medical is a notable advancement in the field of vascular medicine, which has revolutionized stroke prevention and the treatment of carotid artery disease," said Cat Jennings, president, Vascular, Peripheral Interventions, Boston Scientific. "We believe the addition of this clinically differentiated technology to our vascular portfolio demonstrates our continued commitment to provide meaningful innovation for physicians who care for patients with peripheral vascular disease."

"The TCAR system gained U.S. Food and Drug Administration approval in 2015 and is supported by several clinical studies demonstrating a reduced risk of stroke and other complications associated with traditional open surgery. The products sold by Silk Road Medical are the only devices commercially available for use during the TCAR procedure.
Boston Scientific expects to complete the transaction in the second half of 2024, subject to customary closing conditions. Silk Road Medical has guided to net revenue of approximately $194-198 million in 2024, representing 10-12% growth over the prior fiscal year.
The impact to Boston Scientific adjusted earnings per share is expected to be immaterial in 2024 and 2025, and accretive thereafter. We expect the impact to GAAP earnings per share to be less accretive, or dilutive, as the case may be, due to amortization expense and acquisition-related net charges."

From an EBR perspective, EBR market cap currently sits at ~ US$220 million, and still awaits submission of the final module for FDA approval, and thus is still pre-revenue. But it's WISE device is complementary (not in competition with) pacemakers over 90% of which are sold in the US by Boston, Medtronic or Abbott.